Contact

AMADIX: BIOMEDICINE AGAINST CANCER


, ,
Integral service around a transaction
BY : Diego GutiérrezDecember Thu, 2019

Amadix, compañía española de biomedicina enfocada en productos para la detección temprana del cáncer, sells parte de sus acciones por un valor aproximado de 3.2M€.

Of this, €1.2m has been structured through a crowdfunding operation.

The rest has come from the company's shareholders such as CRB Inverbío and Inveready Capital.

Oncology continues to be the therapeutic area with the highest number of investigations.

This is a fact that can be seen in the number of movements that the sector generates in corporate finance.

MEETING AMADIX

It is a Spanish start-up, created in 2010, and specialising in biomedicinewhich provides focus on early detection of cancer.

AMADIX: BIOMEDICINE AGAINST CANCER

In fact, their products are blood tests to detect signs of a future tumour that is not yet present.

This is a very different way of diagnosis from the usual way of diagnosing.

It is currently focused on the early detection of this disease in the colon. Moreover, it is making steady progress in the commercialisation of a test to achieve this.

The main objective of Amadix is to commercialise this technology from 2020.

COLOFAST

This test is called Colofast.

After a normal blood draw, this solution performs a state-of-the-art biomarker analysis where it is able to differentiate between healthy and sick people.

It is able to detect the tumour as pre-malignant lesions that appear before the tumour forms and up to 15 years before showing the first symptoms.

If polyps are detected they are removed and disease does not develop.

Colon cancer is very slow-growing, so if you are screened once a year, there is plenty of scope to tackle the disease even before it starts.

In the coming months, Amadix will also work towards regulatory approval in Europe.

This will ensure that the products to be placed on the market meet the requirements of the European Union.

SCREENING FOR OTHER CANCERS

In addition, the firm is conducting parallel research into how to detect lung cancer very early in healthy smokers with Diagnolungas well as pancreatic cancer in asymptomatic individuals thanks to Pancreadix.

Both solutions, similar to Colofast, are in the clinical validation stage and have an undefined time to market.

The company's main strength is the scientific basis of the products.

For now, the company has its sights set on the US and Europe, especially Spain..

However, he does not rule out probing the Chinese market, where he sees a high growth potential.

According to Rocío Arroyo, CEO of Amadix, "more than fifteen million people at risk in Spain will be able to stay ahead of cancer".

SEVERAL CAPITAL INCREASES

Para hacer frete a los costes derivados de todo esto, ha puesto a la venta parte de sus acciones en una ronda de 1,2M€ through the crowdfunding platform The Crowd Angel.

This amount is the last section of a round of 3.2M€ total.

Amadix partners increased their shareholding in the company, contributing a total of 2,2M€.

Algunos de ellos son, por ejemplo, la red de inversión CRB Inverbío, o fondos de capital riesgo como Inveready.

In 2017, Amadix already achieved 2.8M€ by obtaining assistance through the programme Horizon 2020The European Commission.

Posteriormente, la compañía recibió más de medio millón de euros de Alentia, y fue premiada por el South Summit como la mejor start up of the event in 2018.

OTHER IMPORTANT ROUNDS IN THE SECTOR

MEDLUMICS

Medlumics is a Spanish company medical devices born in 2009.

Its aim is to improve living standards for human beings through technology.

To achieve this, it has recently been able to raise more than 3.5M€ en su última ronda de funding.

VYTRUS BIOTECH

Vytrus biotech was born as a company Spin Off of the Faculty of Pharmacy of the University of Barcelona.

Belonging to the plant biotechnology sector, it is specialising in the production of high-value active ingredientsfor use in the pharmaceutical and cosmetics sector.

In order to continue its growth, last November it attracted more than 1.2M€ in a Series A financing round.

Our diferentiation

Market Research Technology
Our team of market analysis specialists is continuously analyzing the investments of the most active markets in the industry in order to unceasingly contribute ideas of the current market situation and identify the most relevant trends for senior management. We integrate the most relevant sources of information which allows us to discover the most interesting companies for venture capital and similarly helps us to identify the investors with the highest probability of involvement in an M&A process to ensure the success of our sell-side operations.

The reports and deductions of our advisors provide a broad view of the sector, both geographically and from the complementary or adjacent markets perspective.
Technology Data Analytics
for M&A
Advanced data anlytics is a weapon". Intelfin is an artificial intelligence tool we use for investing and creating value in SMEs through competitive analytics and the enterprise environment.

IntelFin consists of a cognitive system, which, through the application of advanced analytical technologies, facilitates the automation of investment and financing decisions in the field of non-listed companies and especially SMEs in high-growth sectors.

The information related to these companies is characterized by their lack of transparency and heterogeneity; thus, it is necessary to develop an advanced analysis which is as much predictive as prescriptive and is developed in a natural language custom, suitable to obtain greater clarity and knowledge of the investment scope.

The IntelFin system focuses especially on analyzing the variables that define and influence the competitive environment of a sector and the positioning of a company, analyzing their influence on future value creation. Therefore, IntelFin supports strategic decision-making to senior management by resolving questions such as:

¿What are my competitors' priorities, strategies and expansion plans? Who's my competition? Which competitor is most likely to grow at a higher rate?
Which areas of activity/business models will receive the most investment? Which sectors are most attractive to investors?
Which companies are going to experience the most growth in the near future? Which companies are most likely to receive investment or be acquired?
Training Methodology
We have developed training programs in an innovative set-up which guarantees our teams the acquisition of technical competences both in the field of corporate finance and in the field of psychology, that is much needed when it comes to negotiation processes.

We have a culture of continuous improvement of our processes, closely related to the use of information systems that allow the enhancement of internal communication between our teams, as well as external communication with our customers. Hence, we extend best practices identified internally in an efficient and rapid manner among our members.

Are you one of those who prefer to be well informed when making decisions?

M&A NEWS
INDUSTRIAL REPORTS
closearrow-circle-o-downchevron-downcrossmenu